Pain, disability, and quality of life in participants after concurrent onabotulinumtoxinA treatment of upper and lower limb spasticity: Observational results from the ASPIRE study.
Ganesh BavikatteGerard E FranciscoWolfgang H JostAlessio BaricichEsther DuarteSimon F T TangMarc SchwartzMariana NelsonTiziana MusacchioAlberto EsquenaziPublished in: PM & R : the journal of injury, function, and rehabilitation (2024)
More than a third of enrolled participants received at least one concurrent onabotA treatment of the upper and lower limbs, with reduced pain, disability, and improved QoL after treatment, consistent with the established safety profile of onabotA for the treatment of spasticity.